相关临床试验
132
17 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1881
进行中（未招募）
12
9.1%
已完成
98
74.2%
Enrolling By Invitation
1
0.8%
尚未招募
4
3.0%
招募中
8
6.1%
终止
3
2.3%
Unknown
5
3.8%
撤回
1
0.8%
暂无批准数据
- The U.S. National Science Foundation announced Project Triad, a first-of-its-kind initiative to integrate quantum sensing, quantum networking, and quantum computing into a single operational system. - The initiative targets applications including GPS-independent navigation, secure communications, resource exploration, and precision medicine, with the goal of moving quantum technology from lab to real-world use. - Project Triad will be supported by three interlocking programs — NSF NQVL, NSF X-Labs, and NSF Quantum+X — bringing together government, academia, and industry to develop and scale integrated quantum technologies. - NSF also announced a separate NSF Engines award to Connecticut's QuantumCT Engine, a $15 million initial investment potentially reaching $160 million over a decade, with industry partners including Boehringer Ingelheim and Pfizer in drug development applications.
- Cerapedics received FDA approval to expand PearlMatrix P-15 Peptide Enhanced Bone Graft indications to include all major lumbar interbody fusion approaches, making it the only Class III drug-device spinal bone graft approved for comprehensive lumbar procedures. - The expansion follows the ASPIRE pivotal study published in Spine, which demonstrated statistically superior fusion speed and composite clinical success compared to local autograft in transforaminal lumbar interbody fusion procedures. - PearlMatrix is now approved for use with titanium alloy and PEEK/titanium interbody fusion cages in addition to original PEEK cages, addressing the lumbar fusion market that represents approximately two-thirds of all fusion procedures. - The approval came within three months of submitting the supplemental application, reflecting the strength of clinical evidence from the rigorous ASPIRE trial that included high-risk patient populations.
- University of Connecticut researchers have developed a protein-based nanoparticle platform that significantly enhances mRNA vaccine stability and effectiveness against Infectious Bronchitis Virus in chickens. - The innovative vaccine demonstrated a 1000-fold increase in antibody titers compared to unvaccinated controls, addressing critical limitations of current live attenuated and killed virus vaccines. - The nanoparticle system uses modified bovine serum albumin to protect mRNA from degradation, potentially eliminating cold chain storage requirements that challenge farm-based vaccine distribution. - Beyond poultry applications, the modular platform technology could accelerate mRNA vaccine development for emerging diseases by allowing rapid incorporation of new genetic sequences.
